University of California San Francisco

Bruce Conklin, MD

Bruce Conklin, MD
Bruce Conklin, MD

Professor, Medicine
School of Medicine

Address

35 Medical Center Way, #903E
San Francisco, CA 94143
United States

Email: [email protected]

ORCID: 0000-0003-1463-6061

Education

Institution Degree Dept or School End Date
University of California San Francisco Molecular Pharmacology 01/1995
Johns Hopkins Hospital Internal Medicine 06/1990
Case Western Reserve School of Medicine M.D. Medicine 06/1988
University of California, Berkeley, CA A.B. Public Health 06/1982

Awards & Honors

Award Conferred By Date
CWRU School of Medicine Distinguished Alumni Award 2016
Fellow, California Academy of Sciences 2011
Scientific American 50 Award 2008
American Society for Clinical Investigation 2003
Medical Resident Research Award-NIDDK 1990

Grants and Funding

  • C9orf72 frontotemporal dementia (FTD) and amyotrophic lateral sclerosis(ALS): using patient cells and CRISPR to reveal therapeutic approaches | NIH | 2021-05-01 - 2026-04-30 | Role: Principal Investigator
  • C9orf72 frontotemporal dementia (FTD) and amyotrophic lateral sclerosis(ALS): using patient cells and CRISPR to reveal therapeutic approaches | NIH | 2021-05-01 - 2024-04-30 | Role: Principal Investigator
  • Therapeutic genome editing to treat Best disease | NIH | 2017-09-30 - 2022-06-30 | Role: Principal Investigator
  • Protein quality control, cardiomyopathy, cardiotoxicity and human isogenic iPSCs | NIH | 2017-07-15 - 2021-06-30 | Role: Principal Investigator
  • Identifying Therapeutic Targets for RNA Splicing-Related Cardiomyopathy | NIH | 2015-12-14 - 2019-11-30 | Role: Principal Investigator
  • Transcriptional Networks During Cardiac Differentiation | NIH | 2007-07-01 - 2018-07-31 | Role: Co-Investigator
  • Induced Pluripotent Stem Cells in the Understanding and Treatment of Heart Diseas | NIH | 2009-09-30 - 2016-10-31 | Role: Co-Principal Investigator
  • Structures of Protein Complexes Regulating Transcription in Enbryonic Stem Cells | NIH | 2010-09-30 - 2016-06-30 | Role: Co-Investigator
  • The Epigenetic Landscape of Heart Development | NIH | 2009-09-30 - 2015-08-31 | Role: Co-Principal Investigator
  • Disease Specific Cardiac Tissue Models | NIH | 2011-09-05 - 2015-05-31 | Role: Co-Principal Investigator
  • Tissue Engineering with a Modular RASSL Toolbox | NIH | 1998-07-01 - 2013-06-30 | Role: Principal Investigator
  • GenMAPP-CS, a dynamic resource pathway analysis | NIH | 2004-08-18 - 2012-07-31 | Role: Principal Investigator
  • Induced pluripotent stem cells in the understanding and treatment of heart diseas | NIH | 2008-12-01 - 2009-05-31 | Role: Co-Principal Investigator
  • GenMAPP: A tool for pathway analysis of genomic data | NIH | 2004-08-18 - 2007-10-31 | Role: Principal Investigator
  • COLLABORATIVE R01--ROLES OF G PROTEINS IN CARDIOMYOPATHY | NIH | 1998-09-30 - 2003-08-31 | Role: Principal Investigator
  • MUTANT G PROTEINS REVEAL SIGNALING PATHWAYS | NIH | 1991-01-01 - 1995-12-31 | Role: Principal Investigator

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 10
  1. Leveraging human genetic variation to therapeutically target hundreds of genes with dominant & dispensable disease alleles.
    Ramey GD, Cowan QT, Saxena AG, Macklin BL, Watry HL, Mei X, Dierks P, Judge LM, Conklin BR, Capra JA| | PubMed
  2. Using image classifiers to predict CMT2A disease-relevant mitochondrial motility phenotypes in iPSC motor neurons.
    Epstein L, Weiner AC, Macklin BL, Kelly KR, Conklin BR, Engelhardt BE| | PubMed
  3. Monitoring biological effects of somatic cell genome editing.
    Freedman BS, Bulte JWM, Conklin BR, Judge LM, Dwinell MR, Geurts AM, Sitton MJ, Mahajan V, Kiani S, Gersbach CA, Ebrahimkhani MR, Kelly JJ, Ronald JA, Morizane R, Gupta N, Shakeri-Zadeh A, Vo N, Saha K, Saxena S, Gamm DM, Sinha D, Tarantal AF, Vandsburger M, Matsubara A, Fu H, Tsai SQ, SCGE Dissemination and Coordinating Center Toolkit Team, SCGE Biological Effects Initiative| | PubMed
  4. Generation of WTD, a control human iPSC line for genetic research.
    Macklin BL, Runyon WV, Feliciano CM, Dierks PH, Kelly KR, Watry HL, Judge LM, Conklin BR| | PubMed
  5. Haplotype editing with CRISPR-Cas9 as a therapeutic approach for dominant-negative missense mutations in NEFL.
    Dua PH, Simon BMJ, Marley CBE, Feliciano CM, Watry HL, Cowan QT, Steury D, Abraham A, Gilbertson EN, Ramey GD, Capra JA, Conklin BR, Judge LM| | PubMed
  6. Characterizing and controlling CRISPR repair outcomes in nondividing human cells.
    Ramadoss GN, Namaganda SJ, Kumar MM, Hamilton JR, Sharma R, Chow KG, Workley LA, Macklin BL, Sun M, Ha AS, Liu JC, Fellmann C, Watry HL, Dierks PH, Bose RS, Jin J, Perez BS, Sandoval Espinoza CR, Matia MP, Lu SH, Judge LM, Shy BR, Nussenzweig A, Adamson B, Murthy N, Doudna JA, Kampmann M, Conklin BR| | PubMed
  7. Programmable epigenome editing by transient delivery of CRISPR epigenome editor ribonucleoproteins.
    Xu D, Besselink S, Ramadoss GN, Dierks PH, Lubin JP, Pattali RK, Brim JI, Christenson AE, Colias PJ, Ornelas IJ, Nguyen CD, Chasins SE, Conklin BR, Nuñez JK| | PubMed
  8. Generation and characterization of a human induced pluripotent stem cell (iPSC) line from a patient with BAG3 P209L myofibrillar myopathy-6.
    Filippi K, Riße I, Judge LM, Conklin BR, Fleischmann BK, Hesse M| | PubMed
  9. Neuronal DNA repair reveals strategies to influence CRISPR editing outcomes.
    Ramadoss GN, Namaganda SJ, Hamilton JR, Sharma R, Chow KG, Macklin BL, Sun M, Liu JC, Fellmann C, Watry HL, Jin J, Perez BS, Espinoza CRS, Matia MP, Lu SH, Judge LM, Nussenzweig A, Adamson B, Murthy N, Doudna JA, Kampmann M, Conklin BR| | PubMed
  10. Dual α-globin-truncated erythropoietin receptor knockin restores hemoglobin production in α-thalassemia-derived erythroid cells.
    Chu SN, Soupene E, Sharma D, Sinha R, McCreary T, Hernandez B, Shen H, Wienert B, Bowman C, Yin H, Lesch BJ, Jia K, Romero KA, Kostamo Z, Zhang Y, Tran T, Cordero M, Homma S, Hampton JP, Gardner JM, Conklin BR, MacKenzie TC, Sheehan VA, Porteus MH, Cromer MK| | PubMed